Human Genome Sciences: Innovative Partnering for Innovative Technology
Even with the funds from its $125 million SmithKline collaboration (which, at the time of its signing, was an unprecedented investment in a biotech licensing), HGS needs plenty more collaborations if it is going to outlive the century. In its joint venture deals with Genetic Therapy Inc. and Isis, HGS is focusing on a strategy of finding third-party licensees, not letting these biotechs create proprietary products themselves.
You may also be interested in...
Pfizer was heavily invested in immuno-oncology combinations five years ago, but following setbacks, the pipeline has shifted considerably, shaped partly by the acquisition of Array.
The possibility, which seems driven by the culture of the times, may be legally possible, but experts raised many practical concerns.
After concerns from the medtech industry that a 2017 final rule requires sponsors with knowledge of off-label use of their product to add it to their label, the US FDA is proposing to delete the confusing text.